India Globalization Capital Appoints Former Congressman Jim Moran to Its Board of Directors
January 19 2022 - 9:29AM
Business Wire
India Globalization Capital, Inc. (NYSE American: IGC) is
excited to announce that the Board has appointed former Congressman
Jim Moran (“Congressman Moran”) as an independent Director. IGC is
delighted to welcome Congressman Moran to its Board of
Directors.
Congressman Moran served Virginia’s 8th Congressional District
for 24 years, where he was known as a “Problem Solver.” Throughout
his tenure, he demonstrated bipartisan leadership and worked across
the aisle to find common ground to resolve complex issues. He
served on the Appropriation, Banking and Finance and Budget
committees. He played a leadership role in the areas of defense,
health, and the environment.
During his 24 years in Congress, Congressman Moran was
recognized as a champion of innovative research and development in
areas including healthcare and national security, environmental
protection and sustainability, and international trade and fiscal
responsibility. He rose to senior leadership on the Appropriations
Committee enabling him to bring billions of dollars into his
Northern Virginia communities of Alexandria, Arlington, and Fairfax
Counties. Having retired after 35 years in elected office,
Congressman Moran is now with a major law firm and represents
international and domestic clients in the defense, technology,
entertainment and international diplomacy sectors. He also serves
in leadership roles for several non-profit foundations and is also
a member of the Government Blockchain Association.
Congressman Moran introduced the AUTISM Educators Act in 2012,
which funded partnerships between public schools and higher
education and non-profit organizations to promote teaching skills
for educators working with high functioning autism students. He
understands that treatment and education for conditions such as
Autism and Alzheimer’s disease have the potential to positively
impact millions of lives.
Congressman Moran received a Master’s Degree in Public
Administration from the University of Pittsburgh Graduate School of
Public and International Affairs and a Bachelors in Economics from
the College of the Holy Cross.
With his extensive experience in Congress and as a policy
advisor on topics including health, technology, and education, we
are confident Congressman Moran will be a great asset to IGC
especially at a time when we pursue Phase 2/3 human trials on IGC-
AD1 on individuals that have Alzheimer’s disease. We look forward
to his guidance in helping us bring new, THC-based investigational
medications into FDA approved clinical trials.
Upon his election to the IGC Board of Directors, Congressman
Moran made the following statement: “I am excited to have an
opportunity to play a role in the growth of an organization
dedicated to scientific and medical research targeted especially at
reducing the pain and loss suffered from Alzheimer’s disease. While
I am aware of the medicinal benefits that marijuana can offer some
individuals, IGC is engaged in clinical research trials that employ
hemp-sourced cannabinoids to facilitate better brain functioning in
subjects that may be vulnerable to Alzheimer’s. If such promising
research is successful, it may have implications for advances in
the understanding of other central nervous disorders.”
About IGC:
India Globalization Capital, Inc. (IGC), headquartered in
Maryland, engages in the development of cannabinoid-based therapies
for healthcare applications. IGC recently completed the first
safety and tolerability clinical trial to treat symptoms of
Alzheimer’s patients using a THC-based investigational new drug.
The Company also operates an infrastructure business based in
India. www.igcinc.us, www.igcpharma.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220118006191/en/
Claudia Grimaldi info@igcinc.us Phone: 301-983-0998
IGC Pharma (AMEX:IGC)
Historical Stock Chart
From Oct 2024 to Nov 2024
IGC Pharma (AMEX:IGC)
Historical Stock Chart
From Nov 2023 to Nov 2024